Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: Squamous Cell Carcinoma of Head and Neck trials

The registry lists 26 Squamous Cell Carcinoma of Head and Neck studies with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor. 22 are open to participants now and 0 have results posted.

Phase 2 15Phase 3 3No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Trilaciclib Combined With Immunochemotherapy for R/M HNSCCNot yet recruitingNCT07679997Phase 2
• Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory StudyNot yet recruitingNCT07137858Phase 2
• PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)Not yet recruitingNCT07090707Phase 2
• Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma SurgeryNot yet recruitingNCT06815705Not applicable
• The Value of CEUS in Assessing the Response of Cervical Lymph Nodes After NACI for HNSCCRecruitingNCT06727162
• Efficacy and Safety of a Third-Course of Neoadjuvant Immunochemotherapy Combined With SBRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients With Stable Disease After Two Treatment Courses: A Single-Arm Exploratory StudyNot yet recruitingNCT06722495Not applicable
• Clinical Outcomes of Thoracodorsal Artery Flap in Oral and Maxillofacial ReconstructionNot yet recruitingNCT06599801
• Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT06576180
• Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT06575322
• Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCCNot yet recruitingNCT06366945Phase 2
• Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell CarcinomaRecruitingNCT06323369Phase 2
• Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)RecruitingNCT06130332Phase 2
• Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and NeckNot yet recruitingNCT06016413Phase 2
• Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell CarcinomaRecruitingNCT06016400Phase 2/3
• PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant ImmunochemotherapyRecruitingNCT05980715Phase 3
• Temporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant TherapyRecruitingNCT05964595
• Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCCRecruitingNCT05941338Phase 2
• Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)RecruitingNCT05582265Phase 3
• Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCCRecruitingNCT05437380Not applicable
• Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)RecruitingNCT05098119Phase 2
• A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCCRecruitingNCT04992559Phase 2
• Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)RecruitingNCT04807140Phase 2
• Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005）Active, not recruitingNCT07267286Phase 2
• Multi-Site Pathological Images-Guided ViT for Oral Squamous Cell Carcinoma Recurrence PredictionCompletedNCT06638762
• Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)Active, not recruitingNCT05724329Phase 2
• Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell CarcinomaActive, not recruitingNCT04718415Phase 2